The primary objective was to evaluate the effect of PCSK9 inhibitors in addition to the background lipid-modifying therapy (LMT), compared with standard LMT in terms of clinical outcomes in patients with coronary CT angiography (CCTA)-detected high-risk plaques.
Subject must be ≥ 18 years.
Degree of stenosis ≥ 50% or plaque burden ≥ 70%
The target lesion is located at the proximal or mid segment of left anterior descending artery, left circumflex artery or right coronary artery.
Subject is able to confirm his/her understanding of the risks, benefits, and treatment alternatives of receiving study-related treatment. He/she or his/her legally authorized representative provides written informed consent prior to any study-related procedure.
Target lesions underwent or planned to revascularization.
Patients with acute coronary syndrome.
New York Heart Association class III or IV, or last known left ventricular ejection fraction < 30%.
Uncontrolled or recurrent ventricular tachycardia.